In NAFLD/NASH patients with type 2 diabetes, SGLT2 inhibitor improves liver enzymes and histological findings, and its administration is, therefore, suggested. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.